Definition

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN) and simultaneously produce interleukin-7 (IL-7) and C-C motif chemokine 19 (CCL19), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, the autologous anti-MSLN CAR-T cells TAK-103 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. IL-7 promotes the proliferation and survival of T cells. CCL19 enhances the migration of T cells and dendritic cells (DCs).